Jennifer Doudna and her team at the Innovative Genomics Institute, UC Berkeley, UCSF, and Gladstone Institutes unveiled a CRISPR‑based tool that slices cancer cells carrying a p53 mutation, present in almost half of all cancers. By targeting the mutant RNA signature, the system activates Cas12a2, shredding chromatin and triggering death in only diseased cells.

The approach mimics bacterial immunity, letting Cas12a2 act as a suicide trigger once it reads a single‑nucleotide change. In mixed cell cultures, the edited enzyme spared healthy cells while eliminating mutant ones, a precision that outpaces conventional chemotherapy’s broad cytotoxicity. This programmable platform could adapt instantly to new oncogenic mutations.

Co‑author Alan Ashworth noted the method could open doors to previously undruggable targets across ovarian, pancreatic, and non‑small‑cell lung cancers. Delivery challenges remain, but the team’s rapid guide‑RNA redesign promise speeds development beyond antibody or small‑molecule therapies. The study, published in Nature, marks a concrete step toward mutation‑specific cancer eradication.

By shattering the entire chromatin landscape, the therapy bypasses the need to rescue dysfunctional p53 protein, sidestepping the lack of druggable pockets that stalled previous efforts. Researchers plan to test the system in animal models next year, aiming to demonstrate safety and efficacy before clinical trials. The technique exemplifies how genome editing can pivot from gene repair to targeted cell elimination.